Literature DB >> 19330552

Esophageal ulcer in a patient who received bevacizumab.

Judith Meza-Junco1, Clarence Wong, Anthony Fields, Michael B Sawyer.   

Abstract

A 60-year-old woman with metastatic rectal cancer who after surgical resection of the primary and creation of a palliative ileostomy in May 2006, was started on a regimen of bevacizumab, irinotecan, 5-fluouracil and leucovorin. After 3 cycles, she presented with solid food dysphagia. An endoscopy showed a large, deep ulcer in the lower third of the esophagus. We assumed that it was related to bevacizumab treatment. Bevacizumab was stopped and she was started on pantoprazole. Over the ensuing months, the ulcer improved notably. To the best of our knowledge, an esophageal ulcer associated with bevacizumab treatment has not been reported. This is likely the precursor lesion to a gastrointestinal tract perforation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19330552     DOI: 10.1007/s10637-009-9246-4

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN: 0167-6997            Impact factor:   3.850


  20 in total

1.  Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab.

Authors:  Frank A Scappaticci; Louis Fehrenbacher; Thomas Cartwright; John D Hainsworth; William Heim; Jordan Berlin; Fairooz Kabbinavar; William Novotny; Somnath Sarkar; Herbert Hurwitz
Journal:  J Surg Oncol       Date:  2005-09-01       Impact factor: 3.454

Review 2.  Bevacizumab in non small cell lung cancer.

Authors:  Alan Sandler
Journal:  Clin Cancer Res       Date:  2007-08-01       Impact factor: 12.531

Review 3.  Cellular and molecular mechanisms of gastrointestinal ulcer healing.

Authors:  Andrzej S Tarnawski
Journal:  Dig Dis Sci       Date:  2005-10       Impact factor: 3.199

Review 4.  Preclinical safety evaluation of rhuMAbVEGF, an antiangiogenic humanized monoclonal antibody.

Authors:  A M Ryan; D B Eppler; K E Hagler; R H Bruner; P J Thomford; R L Hall; G M Shopp; C A O'Neill
Journal:  Toxicol Pathol       Date:  1999 Jan-Feb       Impact factor: 1.902

5.  Barrett's esophagus: prevalence and its relationship with dyspeptic symptoms.

Authors:  Murat Toruner; Irfan Soykan; Arzu Ensari; Isinsu Kuzu; Cihan Yurdaydin; Ali Ozden
Journal:  J Gastroenterol Hepatol       Date:  2004-05       Impact factor: 4.029

6.  Barrett's esophagus: a retrospective analysis of 13 years surveillance.

Authors:  Victoria Switzer-Taylor; Martin Schlup; Ralf Lübcke; Vicki Livingstone; Michael Schultz
Journal:  J Gastroenterol Hepatol       Date:  2008-01-17       Impact factor: 4.029

Review 7.  Bevacizumab, a humanized anti-angiogenic monoclonal antibody for the treatment of colorectal cancer.

Authors:  I Krämer; H-P Lipp
Journal:  J Clin Pharm Ther       Date:  2007-02       Impact factor: 2.512

8.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Authors:  Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

9.  Avoiding bevacizumab related gastrointestinal toxicity for recurrent ovarian cancer by careful patient screening.

Authors:  Fiona Simpkins; Jerome L Belinson; Peter G Rose
Journal:  Gynecol Oncol       Date:  2007-07-23       Impact factor: 5.482

10.  Esophageal ulceration triggers expression of hypoxia-inducible factor-1 alpha and activates vascular endothelial growth factor gene: implications for angiogenesis and ulcer healing.

Authors:  Dolgor Baatar; Michael K Jones; Koji Tsugawa; Rama Pai; Woo S Moon; Gou Y Koh; Injune Kim; Seigo Kitano; Andrzej S Tarnawski
Journal:  Am J Pathol       Date:  2002-10       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.